Pyxis Oncology Stock In Shambles: Down -73% With 7-Day Losing Streak
Pyxis Oncology (PYXS) stock hit day 7 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -73% return. The company has lost about $201 Mil in value over the last 7 days, with its current market capitalization at about $74 Mil. The stock remains 23.7% below its value at the end of 2024. This compares with year-to-date returns of 16.9% for the S&P 500.
Pyxis Oncology’s recent streak reflects investor apprehension following preliminary Phase 1 data for its cancer drug, MICVO. Despite promising response rates, concerns mounted over a 28% patient discontinuation rate due to adverse events and the trial’s small sample size, raising questions about data interpretability and tolerability. This overshadowed an $11 million royalty sale, with a lack of near-term catalysts and ongoing cash burn amplifying market skepticism.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.For quick background, PYXS offers development of immune-oncology therapies, including a siglec-15 targeting antibody for treating thyroid cancer, head and neck squamous cell carcinoma, NSCLC, and other solid tumors.
Comparing PYXS Stock Returns With The S&P 500
The following table summarizes the return for PYXS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | PYXS | S&P 500 |
|---|---|---|
| 1D | -6.7% | 0.6% |
| 7D (Current Streak) | -73.0% | -0.3% |
| 1M (21D) | -73.7% | 5.2% |
| 3M (63D) | -45.7% | 3.3% |
| YTD 2025 | -23.7% | 16.9% |
| 2024 | -13.3% | 23.3% |
| 2023 | 34.3% | 24.2% |
| 2022 | -87.8% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 131 S&P constituents with 3 days or more of consecutive gains and 34 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 95 | 21 |
| 4D | 27 | 3 |
| 5D | 6 | 8 |
| 6D | 1 | 1 |
| 7D or more | 2 | 1 |
| Total >=3 D | 131 | 34 |
Key Financials for Pyxis Oncology (PYXS)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $16.1 Mil |
| Operating Income | $-82.2 Mil | $-68.5 Mil |
| Net Income | $-73.8 Mil | $-77.3 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $2.8 Mil | $0 |
| Operating Income | $-19.8 Mil | $-23.5 Mil |
| Net Income | $-18.4 Mil | $-22.0 Mil |
The losing streak PYXS stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.